TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.2.1. Rising prevalence of acute agitation and aggression
4.2.2. Increase in focus on creating awareness about agitation and aggression
4.3. Restraints
4.3.1. Social stigma associated with mental illness
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS
6.1. Overview
6.2. First-Generation Anti-Psychotics
6.3. Second-Generation Anti-Psychotics
6.4. Benzodiazepines
6.5. Others
7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Oral
7.3. Intramuscular
7.4. Others
8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION
8.1. Overview
8.2. Schizophrenia
8.3. Dementia
8.4. Bipolar Disorder
8.5. Depression
8.6. Drug-induced Agitation and Aggression
8.7. Alcohol Withdrawal
8.8. Others
9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER
9.1. Overview
9.2. Hospitals & Clinics
9.3. Psychiatric Care Facilities
9.4. Others
10. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Acute Agitation and Aggression Treatment Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Acute Agitation and Aggression Treatment Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure. 2022
12. COMPANY PROFILES
12.1. Eli Lilly and Company
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Pfizer Inc
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. GlaxoSmithKline plc
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Teva Pharmaceutical Industries Ltd
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Otsuka Holdings Co., Ltd
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. VIATRIS INC
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Johnson & Johnson Services, Inc
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. H. Lundbeck A/S
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Amneal Pharmaceuticals LLC
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SYNOPSIS, 2019–2032
TABLE 2 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, ESTIMATES & FORECAST, 2019–2032 (USD MILLION)
TABLE 3 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 4 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 5 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 6 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 7 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 8 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 9 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 10 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 11 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 12 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 13 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 14 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 15 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 16 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 17 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 18 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 1 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 2 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 3 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 4 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 5 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 6 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 7 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 8 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 9 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 10 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 11 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 12 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 13 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 14 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 15 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 16 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 17 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 18 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 19 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 20 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 21 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 22 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 23 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 24 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END UER, 2019–2032 (USD MILLION)
TABLE 25 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 26 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 27 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 28 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 29 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 30 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 31 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 32 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 33 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 34 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 35 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 36 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 37 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 38 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 39 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 40 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 41 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 42 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 43 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 44 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 45 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 46 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 47 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 48 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 49 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 50 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 51 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 52 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 53 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 54 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 55 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 56 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 57 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 58 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 59 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 60 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 61 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 62 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 63 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 64 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 65 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 66 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 67 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 68 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
TABLE 69 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)
TABLE 70 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)
TABLE 71 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)
TABLE 72 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET
FIGURE 4 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY DRUG CLASS, 2022
FIGURE 5 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022
FIGURE 6 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY INDICATION, 2022
FIGURE 7 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY END USER, 2022
FIGURE 8 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 13 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 14 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 16 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 PFIZER INC: SWOT ANALYSIS
FIGURE 18 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
FIGURE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
FIGURE 22 OTSUKA HOLDINGS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 OTSUKA HOLDINGS CO., LTD.: SWOT ANALYSIS
FIGURE 24 VIATRIS INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 VIATRIS INC: SWOT ANALYSIS
FIGURE 26 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 NOVARTIS AG: SWOT ANALYSIS
FIGURE 30 H. LUNDBECK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 H. LUNDBECK A/S: SWOT ANALYSIS
FIGURE 32 AMNEAL PHARMACEUTICALS LLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AMNEAL PHARMACEUTICALS LLC: SWOT ANALYSIS
